FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996475257> ?p ?o ?g. }

• W2996475257 endingPage "e177" @default.
• W2996475257 startingPage "e177" @default.
• W2996475257 abstract "Objective To characterize immunohistochemically a group of oral myofibroblastic lesions (MLs). Study Design MLs incorporated during the period of 1997-2014 were retrieved from the files and records of the Department of Oral Pathology. Cases of myofibroma (MF), nodular fasciitis (NF), desmoplastic fibroma (DF), and 2 myofibroblastic sarcoma (MS) were stained with antibodies against alpha-smooth muscle actin (α-SMA), H-caldesmon, vimentin, desmin, β-catenin, anaplastic lymphoma protein kinase (ALK-1), and Ki-67. Results Nineteen of 22 cases of MF, 2/5 NF, 1/10 DF, and 1/2 MS were positive for α-SMA. All cases of MF, NF, DF, and MS were positive for vimentin. One-half of MS cases were positive for desmin. Six out of 10 cases of DF were positives for β-catenin. Two cases of MF were positive for ALK-1. All cases of MF, NF, DF, and MS were negative for H-caldesmon. The Ki-67 labeling index was 10% and 8/22 cases of MF, 3/5 cases of NF, and 2/2 cases of MS exhibited a rate of ≥ 10% for this marker. Conclusions The application of this panel of markers can help the diagnosis of oral MLs, in particular the distinction between fibroblastic, myofibroblastic, and muscle cells proliferation. To characterize immunohistochemically a group of oral myofibroblastic lesions (MLs). MLs incorporated during the period of 1997-2014 were retrieved from the files and records of the Department of Oral Pathology. Cases of myofibroma (MF), nodular fasciitis (NF), desmoplastic fibroma (DF), and 2 myofibroblastic sarcoma (MS) were stained with antibodies against alpha-smooth muscle actin (α-SMA), H-caldesmon, vimentin, desmin, β-catenin, anaplastic lymphoma protein kinase (ALK-1), and Ki-67. Nineteen of 22 cases of MF, 2/5 NF, 1/10 DF, and 1/2 MS were positive for α-SMA. All cases of MF, NF, DF, and MS were positive for vimentin. One-half of MS cases were positive for desmin. Six out of 10 cases of DF were positives for β-catenin. Two cases of MF were positive for ALK-1. All cases of MF, NF, DF, and MS were negative for H-caldesmon. The Ki-67 labeling index was 10% and 8/22 cases of MF, 3/5 cases of NF, and 2/2 cases of MS exhibited a rate of ≥ 10% for this marker. The application of this panel of markers can help the diagnosis of oral MLs, in particular the distinction between fibroblastic, myofibroblastic, and muscle cells proliferation." @default.
• W2996475257 created "2019-12-26" @default.
• W2996475257 creator A5003455971 @default.
• W2996475257 creator A5012057990 @default.
• W2996475257 creator A5030939461 @default.
• W2996475257 creator A5033277649 @default.
• W2996475257 creator A5035500261 @default.
• W2996475257 creator A5068333130 @default.
• W2996475257 creator A5089661479 @default.
• W2996475257 date "2020-01-01" @default.
• W2996475257 modified "2023-10-18" @default.
• W2996475257 title "MYOFIBROBLASTIC LESIONS IN THE ORAL CAVITY: IMMUNOHISTOCHEMICAL ANALYSIS" @default.
• W2996475257 doi "https://doi.org/10.1016/j.oooo.2019.06.751" @default.
• W2996475257 hasPublicationYear "2020" @default.
• W2996475257 type Work @default.
• W2996475257 sameAs 2996475257 @default.
• W2996475257 citedByCount "0" @default.
• W2996475257 crossrefType "journal-article" @default.
• W2996475257 hasAuthorship W2996475257A5003455971 @default.
• W2996475257 hasAuthorship W2996475257A5012057990 @default.
• W2996475257 hasAuthorship W2996475257A5030939461 @default.
• W2996475257 hasAuthorship W2996475257A5033277649 @default.
• W2996475257 hasAuthorship W2996475257A5035500261 @default.
• W2996475257 hasAuthorship W2996475257A5068333130 @default.
• W2996475257 hasAuthorship W2996475257A5089661479 @default.
• W2996475257 hasConcept C142724271 @default.
• W2996475257 hasConcept C147447768 @default.
• W2996475257 hasConcept C204232928 @default.
• W2996475257 hasConcept C2776460901 @default.
• W2996475257 hasConcept C2778256501 @default.
• W2996475257 hasConcept C2779072444 @default.
• W2996475257 hasConcept C2780534256 @default.
• W2996475257 hasConcept C2780801072 @default.
• W2996475257 hasConcept C71924100 @default.
• W2996475257 hasConceptScore W2996475257C142724271 @default.
• W2996475257 hasConceptScore W2996475257C147447768 @default.
• W2996475257 hasConceptScore W2996475257C204232928 @default.
• W2996475257 hasConceptScore W2996475257C2776460901 @default.
• W2996475257 hasConceptScore W2996475257C2778256501 @default.
• W2996475257 hasConceptScore W2996475257C2779072444 @default.
• W2996475257 hasConceptScore W2996475257C2780534256 @default.
• W2996475257 hasConceptScore W2996475257C2780801072 @default.
• W2996475257 hasConceptScore W2996475257C71924100 @default.
• W2996475257 hasIssue "1" @default.
• W2996475257 hasLocation W29964752571 @default.
• W2996475257 hasOpenAccess W2996475257 @default.
• W2996475257 hasPrimaryLocation W29964752571 @default.
• W2996475257 hasRelatedWork W1993992369 @default.
• W2996475257 hasRelatedWork W2075290631 @default.
• W2996475257 hasRelatedWork W2127443195 @default.
• W2996475257 hasRelatedWork W2145691556 @default.
• W2996475257 hasRelatedWork W2162663678 @default.
• W2996475257 hasRelatedWork W2236651 @default.
• W2996475257 hasRelatedWork W2400236695 @default.
• W2996475257 hasRelatedWork W2412069906 @default.
• W2996475257 hasRelatedWork W2463033561 @default.
• W2996475257 hasRelatedWork W2889036282 @default.
• W2996475257 hasVolume "129" @default.
• W2996475257 isParatext "false" @default.
• W2996475257 isRetracted "false" @default.
• W2996475257 magId "2996475257" @default.
• W2996475257 workType "article" @default.